484 articles in this topic
A randomized trial shows hormone receptor-positive/HER2+ early breast cancer patients had 100% 5-year overall survival with endocrine therapy plus dual HER2 blockade.
Orally bioavailable cyclin A/B RxL inhibitors exploit a cell-cycle vulnerability in small-cell lung cancer and other G1-S-checkpoint-deficient tumors.
AML stem cells produce BHB via autonomous ketogenesis to block ferroptosis, revealing a targetable metabolic vulnerability in leukemia.
Scientists identify CD300ld as a key mechanism by which tumor-infiltrating neutrophils silence CD8+ T cells, opening a new immunotherapy target.
A prospective cohort study shows combining ctDNA with PSA levels dramatically improves survival prediction in high-volume metastatic prostate cancer patients.
Stanford scientists used RFdiffusion and ProteinMPNN to build a compact α-helical TCR mimic with 9.5 nM affinity for a tumor antigen — and near-perfect peptide specificity.
A new machine learning tool called MaNeo scans tumor peptides to identify neoantigens that activate T cells against cancer while sparing healthy cells.
A massive 857-study meta-analysis maps hepatitis B and C contributions to liver cancer across 81 countries, revealing stark regional disparities.
A phase 1 trial of a neoantigen DNA vaccine for glioblastoma found strong immune responses and survival rates exceeding historical benchmarks.
A phase 3 trial finds nivolumab-based regimens offer no survival advantage over durvalumab for unresectable stage III NSCLC.
A newly identified enzyme links lactate metabolism to liver cancer progression, and a natural compound delivered via nanoparticles shows striking anti-tumor results.
Cambridge scientists engineer a nanoprobe that detects therapy-induced senescence non-invasively through a simple urine colorimetric test.
